Tag Archive for: olaparib
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025